GlassScriptPhysician profile
Tehmina A Badar
NPI 1639154883
$10,202.04
in general payments reported to CMS, 2019-2025
43 companies · $2,650 in 2025
The $2,650 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $671 · 2021: $1,159 · 2022: $1,282 · 2023: $1,607 · 2024: $2,103 · 2025: $2,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,192 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,192.04 |
| Education | $167.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,281.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,302.09 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $588.71 | 2021-2025 | Dupixent |
| Shionogi INC | $572.51 | 2021-2025 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $513.65 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $498.70 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $443.56 | 2019-2025 | (Ak6) Vest Therapy, Alt Therapies Undivided |
| Mylan Specialty L.P. | $436.28 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $400.31 | 2021-2025 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $367.61 | 2021-2025 | Acthar |
| Abbvie INC. | $297.85 | 2021-2025 | Avycaz, Teflaro |
| Ani Pharmaceuticals, INC. | $287.95 | 2022-2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $259.69 | 2021-2023 | Hetlioz |
| Electromed, INC. | $219.87 | 2021-2024 | Smartvest |
| Harmony Biosciences LLC | $204.49 | 2022-2025 | Wakix |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $154.09 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $147.09 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $143.49 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $120.75 | 2019-2020 | |
| Medtronic, INC. | $78.54 | 2023 | Illumisite |
| Genzyme Corporation | $76.64 | 2021-2024 | |
| Tactile Systems Technology INC | $71.25 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Pulmonx Corporation | $70.79 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mallinckrodt Enterprises LLC | $62.01 | 2019 | |
| Inogen, INC. | $55.64 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen One G3 Oxygen Concentrator |
| Olympus America INC. | $52.37 | 2019-2020 | |
| Intuitive Surgical, INC. | $49.50 | 2023-2025 | Da Vinci Surgical System |
| Janssen Pharmaceuticals, INC | $42.99 | 2021-2022 | |
| Allergan, INC. | $39.78 | 2019-2020 | |
| Circassia INC. | $39.23 | 2019-2020 | |
| Veran Medical Technologies, INC. | $38.98 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $38.72 | 2023-2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $35.93 | 2021 | |
| Melinta Therapeutics, LLC | $31.34 | 2023 | Vabomere |
| Merck Sharp & Dohme LLC | $28.03 | 2025 | Winrevair |
| Pfizer INC. | $25.33 | 2022 | |
| Inspire Medical Systems, INC. | $24.50 | 2023 | Inspire |
| Amgen INC. | $21.73 | 2024 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $21.29 | 2021 | |
| Lilly USA, LLC | $20.15 | 2025 | Zepbound |
| Ethicon INC. | $18.96 | 2025 | Monarch Platform |
| Genentech USA, INC. | $15.56 | 2019 | |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tehmina Badar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.